362 related articles for article (PubMed ID: 30538458)
1. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of tDodSNO generates a photoactivated nitric oxide releasing nanoparticle for localized control of vasodilation and vascular hyperpermeability.
Alimoradi H; Barzegar-Fallah A; Sammut IA; Greish K; Giles GI
Free Radic Biol Med; 2019 Jan; 130():297-305. PubMed ID: 30367997
[TBL] [Abstract][Full Text] [Related]
3. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
4. RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy.
Wu SH; Hsieh CC; Hsu SC; Yao M; Hsiao JK; Wang SW; Lin CP; Huang DM
J Adv Res; 2021 May; 30():185-196. PubMed ID: 34026295
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
6. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
[TBL] [Abstract][Full Text] [Related]
7. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
10. The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer.
Greish K; Taurin S; Morsy MA
Ther Deliv; 2018 May; 9(5):333-342. PubMed ID: 29681232
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
[TBL] [Abstract][Full Text] [Related]
13. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
Sun G; Sun K; Sun J
Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
[TBL] [Abstract][Full Text] [Related]
14. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
15. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
16. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release.
Zhang Y; Xiao Y; Huang Y; He Y; Xu Y; Lu W; Yu J
Colloids Surf B Biointerfaces; 2020 Apr; 188():110772. PubMed ID: 31999965
[TBL] [Abstract][Full Text] [Related]
18. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.
Kutlehria S; Behl G; Patel K; Doddapaneni R; Vhora I; Chowdhury N; Bagde A; Singh M
AAPS PharmSciTech; 2018 Feb; 19(2):792-802. PubMed ID: 29019073
[TBL] [Abstract][Full Text] [Related]
19. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
[TBL] [Abstract][Full Text] [Related]
20. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]